Pneumonia in Children in Developing Countries

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 697)


Pneumonia is the commonest cause of death in children [1, 2]. The World Health Organization (WHO) and UNICEF estimate that pneumonia is the primary cause of 19% of all deaths in children less than 5 years of age. In addition, most of the 10% of deaths caused by neonatal sepsis are associated with pneumonia and bacterial pneumonia is an important factor in many of the deaths caused by measles, pertussis and HIV [2]. Pneumonia therefore causes approximately one-third of all child deaths. Far too little effort has gone into research on pneumonia and its prevention and treatment.


Acute Respiratory Infection Severe Pneumonia Bacterial Pneumonia Pneumococcal Vaccine Measle Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008 May;86(5):408–16.CrossRefPubMedGoogle Scholar
  2. 2.
    Wardlaw T, Salama P, Johansson EW, Mason E. Pneumonia: the leading killer of children. Lancet. 2006 Sep 23;368(9541):1048–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Chretien J, Holland W, Macklem P, Murray J, Woolcock A. Acute respiratory infections in children. A global public-health problem. N Engl J Med. 1984 Apr 12;310(15):982–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Walsh JA, Warren KS. Selective primary health care: an interim strategy for disease control in developing countries. N Engl J Med. 1979 Nov 1;301(18):967–74.CrossRefPubMedGoogle Scholar
  5. 5.
    Bulla A, Hitze K. Acute respiratory infections: a review. Bull World Health Organ. 1978;56(3):481–98.PubMedGoogle Scholar
  6. 6.
    Monto AS, Johnson KM. Respiratory infections in the American tropics. Am J Trop Med Hyg. 1968 Nov;17(6):867–74.PubMedGoogle Scholar
  7. 7.
    Sobĕslavský O, Sebikari SR, Harland PS, Skrtić N, Fayinka OA, Soneji AD. The viral etiology of acute respiratory infections in children in Uganda. Bull World Health Organ. 1977;55(5):625–31.PubMedGoogle Scholar
  8. 8.
    Shann F. Etiology of severe pneumonia in children in developing countries. Pediatr Infect Dis. 1986 Apr;5(2):247–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Shann F, Gratten M, Germer S, Linnemann V, Hazlett D, Payne R. Aetiology of pneumonia in children in Goroka Hospital, Papua New Guinea. Lancet. 1984 Sep 8;2(8402):537–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Shann F. Haemophilus influenzae pneumonia: type b or non-type b? Lancet. 1999 Oct 30;354(9189):1488–90.CrossRefPubMedGoogle Scholar
  11. 11.
    World Health Organization. Clinical management of acute respiratory infections in children: a WHO memorandum. Bull World Health Organ. 1981;59(5):707–16.Google Scholar
  12. 12.
    Shann F, Hart K, Thomas D. Acute lower respiratory tract infections in children: possible criteria for selection of patients for antibiotic therapy and hospital admission. Bull World Health Organ. 1984;62(5):749–53.PubMedGoogle Scholar
  13. 13.
    World Health Organization. Case management of acute respiratory infections in children in developing countries. Geneva: WHO; 1985.Google Scholar
  14. 14.
    World Health Organization. Respiratory infections in children: management at small hospitals. Background notes and a manual for doctors. Geneva: WHO; 1986.Google Scholar
  15. 15.
    Shann F. Bacterial pneumonia: commoner than perceived. Lancet. 2001 June 30;357(9274):2070–2.CrossRefPubMedGoogle Scholar
  16. 16.
    Pio A. Standard case management of pneumonia in children in developing countries: the cornerstone of the acute respiratory infection programme. Bull World Health Organ. 2003;81(4):298–300.PubMedGoogle Scholar
  17. 17.
    World Health Organization. Pocket book of hospital care for children. Geneva: WHO; 2005.Google Scholar
  18. 18.
    World Health Organization. Integrated management of childhood illness chart booklet. Geneva: WHO; 2008.Google Scholar
  19. 19.
    Harari M, Shann F, Spooner V, Meisner S, Carney M, de Campo J. Clinical signs of pneumonia in children. Lancet. 1991 Oct 12;338(8772):928–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Shann F. The management of pneumonia in children in developing countries. Clin Infect Dis. 1995 Dec;21(Suppl 3):S218–25.Google Scholar
  21. 21.
    Ayieko P, English M. Case management of childhood pneumonia in developing countries. Pediatr Infect Dis J. 2007 May;26(5):432–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Shann F. WHO definition of tachypnoea in children. Lancet. 1992 Jan 18;339(8786):176–7.CrossRefGoogle Scholar
  23. 23.
    Addo-Yobo E, Chisaka N, Hassan M, Hibberd P, Lozano JM, Jeena P, et al. Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study. Lancet. 2004 Oct 25;364(9440):1141–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet. 2008 Jan 5;371(9606):49–56.CrossRefPubMedGoogle Scholar
  25. 25.
    Shann F, Barker J, Poore P. Clinical signs that predict death in children with severe pneumonia. Pediatr Infect Dis J. 1989 Dec;8(12):852–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Nunn JF. Nunn’s Applied Respiratory Physiology. 4th ed. Stoneham, MA: Butterworth-Heinemann; 1993. pp. 472–81.Google Scholar
  27. 27.
    Shann F. Oxygen delivery: nasopharyngeal catheter or nasal prongs? J Pediatr. 1996 Jul;129(1):185. Author reply 186.Google Scholar
  28. 28.
    Shann F, Linnemann V, Gratten M. Serum concentrations of penicillin after intramuscular administration of procaine, benzyl, and benethamine penicillin in children with pneumonia. J Pediatr. 1987 Feb;110(2):299–302.CrossRefPubMedGoogle Scholar
  29. 29.
    Straus WL, Qazi SA, Kundi Z, Nomani NK, Schwartz B. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxicillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group. Lancet. 1998 July 25;352(9124):270–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Leiberman A, Leibovitz E, Piglansky L, Raiz S, Press J, Yagupsky P, et al. Bacteriologic and clinical efficacy of trimethoprim–sulfamethoxazole for treatment of acute otitis media. Pediatr Infect Dis J. 2001 Mar;20(3):260–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Dagan R, Schneider S, Givon-Lavi N, Greenberg D, Leiberman A, Jacobs MR, et al. Failure to achieve early bacterial eradication increases clinical failure rate in acute otitis media in young children. Pediatr Infect Dis J. 2008 Mar;27(3):200–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Campbell H, Byass P, Forgie IM, O’Neill KP, Lloyd-Evans N, Greenwood BM. Trial of co-trimoxazole versus procaine penicillin with ampicillin in treatment of community-acquired pneumonia in young Gambian children. Lancet. 1988 Nov 19;2(8621):1182–4.CrossRefGoogle Scholar
  33. 33.
    Keeley DJ, Nkrumah FK, Kapuyanyika C. Randomized trial of sulfamethoxazole + trimethoprim versus procaine penicillin for the outpatient treatment of childhood pneumonia in Zimbabwe. Bull World Health Organ. 1990;68(2):185–92.PubMedGoogle Scholar
  34. 34.
    Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1–10. Quiz 11–12.Google Scholar
  35. 35.
    Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther. 2008 Oct;6(5):619–35.Google Scholar
  36. 36.
    World Health Organization. Technical updates of the guidelines on the integrated management of childhood illness (IMCI). Geneva: WHO; 2005.Google Scholar
  37. 37.
    Fonseca W, Hoppu K, Rey LC, Amaral J, Qazi S. Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. Antimicrob Agents Chemother. 2003 Mar;47(3):997–1001.Google Scholar
  38. 38.
    Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect Dis. 2002 Oct;2(10):593–604.Google Scholar
  39. 39.
    American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics. 2004 May;113(5):1451–65.Google Scholar
  40. 40.
    Hazir T, Qazi SA, Bin Nisar Y, Maqbool S, Asghar R, Iqbal I, et al. Comparison of standard versus double dose of amoxicillin in the treatment of non-severe pneumonia in children aged 2–59 months: a multi-centre, double blind, randomised controlled trial in Pakistan. Arch Dis Child. 2007 Apr;92(4):291–7.Google Scholar
  41. 41.
    Haider BA, Saeed MA, Bhutta ZA. Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev. 2008;2:CD005976.PubMedGoogle Scholar
  42. 42.
    Haynes J, Hawkey PM, Williams EW. The in-vitro activity of combinations of penicillin and gentamicin against penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. J Antimicrob Chemother. 1986 Sep;18(3):426–8.Google Scholar
  43. 43.
    Friedland IR, Paris M, Shelton S, McCracken GH. Time-kill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae. J Antimicrob Chemother. 1994 Aug;34(2):231–7.Google Scholar
  44. 44.
    Gross ME, Giron KP, Septimus JD, Mason EO, Musher DM. Antimicrobial activities of beta-lactam antibiotics and gentamicin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother. 1995 May;39(5):1166–8.Google Scholar
  45. 45.
    Darras-Joly C, Bédos JP, Sauve C, Moine P, Vallée E, Carbon C et al. Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother. 1996 Sep;40(9):2147–51.Google Scholar
  46. 46.
    Schlegel L, Sissia G, Fremaux A, Geslin P. In-vitro killing activity of combinations of beta-lactam agents with aminoglycosides against penicillin-resistant pneumococci. J Antimicrob Chemother. 1997 Jan;39(1):95–8.Google Scholar
  47. 47.
    Anadiotis L, Maskell JP, Sefton AM. Comparative in-vitro activity of penicillin alone and combined with gentamicin against clinical isolates of Streptococcus pneumoniae with decreased susceptibility to penicillin. Int J Antimicrob Agents. 2002 Mar;19(3):173–81.Google Scholar
  48. 48.
    English M, Mohammed S, Ross A, Ndirangu S, Kokwaro G, Shann F, et al. A randomised, controlled trial of once daily and multi-dose daily gentamicin in young Kenyan infants. Arch Dis Child. 2004 Jul;89(7):665–9.Google Scholar
  49. 49.
    Sanders CC. Novel resistance selected by the new expanded-spectrum cephalosporins: a concern. J Infect Dis. 1983 Mar;147(3):585–9.Google Scholar
  50. 50.
    Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 1964 May;60:759–76.PubMedGoogle Scholar
  51. 51.
    Duke T, Poka H, Dale F, Michael A, Mgone J, Wal T. Chloramphenicol versus benzylpenicillin and gentamicin for the treatment of severe pneumonia in children in Papua New Guinea: a randomised trial. Lancet. 2002 Feb 9;359(9305):474–80.Google Scholar
  52. 52.
    Asghar R, Banajeh S, Egas J, Hibberd P, Iqbal I, Katep-Bwalya M, et al. Chloramphenicol versus ampicillin plus gentamicin for community acquired very severe pneumonia among children aged 2–59 months in low resource settings: multicentre randomised controlled trial (SPEAR study). BMJ. 2008 Jan 12;336(7635):80–4.Google Scholar
  53. 53.
    Hazir T, Qazi SA, Nisar YB, Maqbool S, Asghar R, Iqbal I, et al. Can WHO therapy failure criteria for non-severe pneumonia be improved in children aged 2–59 months?. Int J Tuberc Lung Dis. 2006 Aug;10(8):924–31.PubMedGoogle Scholar
  54. 54.
    Subhi R, Adamson M, Campbell H, Weber M, Smith K, Duke T. The prevalence of hypoxaemia among ill children in developing countries: a systematic review. Lancet Infect Dis. 2009 Apr;9(4):219–27.CrossRefPubMedGoogle Scholar
  55. 55.
    World Health Organization. Oxygen therapy for acute respiratory infections in young children in developing countries. Geneva: WHO; 1993.Google Scholar
  56. 56.
    Duke T, Wandi F, Jonathan M, Matai S, Kaupa M, Saavu M, et al. Improved oxygen systems for childhood pneumonia: a multihospital effectiveness study in Papua New Guinea. Lancet. 2008 Oct 11;372(9646):1328–33.CrossRefPubMedGoogle Scholar
  57. 57.
    World Health Organization. World health statistics 2009. Geneva: WHO; 2009.Google Scholar
  58. 58.
    Dreyfuss D, Leviel F, Paillard M, Rahmani J, Coste F. Acute infectious pneumonia is accompanied by a latent vasopressin-dependent impairment of renal water excretion. Am Rev Respir Dis. 1988 Sep;138(3):583–9.PubMedGoogle Scholar
  59. 59.
    Singhi S, Sharma A, Majumdar S. Body water and plasma volume in severe community-acquired pneumonia: implications for fluid therapy. Ann Trop Paediatr. 2005 Dec;25(4):243–52.CrossRefPubMedGoogle Scholar
  60. 60.
    Shann F. Paediatric fluid and electrolyte therapy. In: Berston AD, Soni N, editors. Oh’s intensive care manual. Philadelphia, PA: Elsevier; 2008. p. 1117–24.Google Scholar
  61. 61.
    Guppy MPB, Mickan SM, Del Mar CB. “Drink plenty of fluids”: a systematic review of evidence for this recommendation in acute respiratory infections. BMJ. 2004 Feb 28;328(7438):499–500.CrossRefPubMedGoogle Scholar
  62. 62.
    Shann F. Antipyretics in severe sepsis. Lancet. 1995 Feb 11;345(8946):338.Google Scholar
  63. 63.
    Plaisance KI, Kudaravalli S, Wasserman SS, Levine MM, Mackowiak PA. Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections. Pharmacotherapy. 2000 Dec;20(12):1417–22.CrossRefPubMedGoogle Scholar
  64. 64.
    Doran TF, De Angelis C, Baumgardner RA, Mellits ED. Acetaminophen: more harm than good for chickenpox? J Pediatr. 1989 Jun;114(6):1045–8.Google Scholar
  65. 65.
    Brandts CH, Ndjavé M, Graninger W, Kremsner PG. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet. 1997 Sep 6;350(9079):704–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Thaver D, Zaidi AKM. Burden of neonatal infections in developing countries: a review of evidence from community-based studies. Pediatr Infect Dis J. 2009 Jan;28(1 Suppl):S3–9.Google Scholar
  67. 67.
    Chisti MJ, Tebruegge M, La Vincente S, Graham SM, Duke T. Pneumonia in severely malnourished children in developing countries – mortality risk, aetiology and validity of WHO clinical signs: a systematic review. Trop Med Int Health. 2009 Oct;14(10):1173–89.CrossRefPubMedGoogle Scholar
  68. 68.
    Graham SM, English M, Hazir T, Enarson P, Duke T. Challenges to improving case management of childhood pneumonia at health facilities in resource-limited settings. Bull World Health Organ. 2008 May;86(5):349–55.CrossRefPubMedGoogle Scholar
  69. 69.
    McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, Cassol S, et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet. 2007 Apr 28;369(9571):1440–51.CrossRefPubMedGoogle Scholar
  70. 70.
    Sazawal S, Black RE. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials. Lancet Infect Dis. 2003 Sep;3(9):547–56.CrossRefPubMedGoogle Scholar
  71. 71.
    Grant GB, Campbell H, Dowell SF, Graham SM, Klugman KP, Mulholland EK, et al. Recommendations for treatment of childhood non-severe pneumonia. Lancet Infect Dis. 2009 Mar;9(3):185–96.CrossRefPubMedGoogle Scholar
  72. 72.
    Scott JAG, English M. What are the implications for childhood pneumonia of successfully introducing Hib and pneumococcal vaccines in developing countries? PLoS Med. 2008 Apr 22;5(4):e86.Google Scholar
  73. 73.
    Shann F. The non-specific effects of vaccines. Arch Dis Child. 2010 Sep;95(9):662–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Healy CM, Baker CJ. Prospects for prevention of childhood infections by maternal immunization. Curr Opin Infect Dis. 2006 Jun;19(3):271–6.CrossRefPubMedGoogle Scholar
  75. 75.
    Quiambao BP, Nohynek HM, Käyhty H, Ollgren JP, Gozum LS, Gepanayao CP, et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine. 2007 May 30;25(22):4470–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Almeida VDC, Mussi-Pinhata MM, De Souza CBS, Kubo CA, Martinez EZ, Carneiro-Sampaio MM, et al. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants. Vaccine. 2009 Jun 12;27(29):3856–61.CrossRefGoogle Scholar
  77. 77.
    Shann F. Giving pneumococcal vaccine to mothers. Vaccine. 2007 Aug 14;25(33):6147.CrossRefPubMedGoogle Scholar
  78. 78.
    Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003 Oct 2;349(14):1341–8.CrossRefPubMedGoogle Scholar
  79. 79.
    Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005 Apr 26;365(9465):1139–46.CrossRefPubMedGoogle Scholar
  80. 80.
    Lucero MG, Nohynek H, Williams G, Williams V, Simões EAF, Lupisan S, et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J. 2009 Jun;28(6):455–62.CrossRefPubMedGoogle Scholar
  81. 81.
    Levine OS, Lagos R, Muñoz A, Villaroel J, Alvarez AM, Abrego P, et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J. 1999 Dec;18(12):1060–4.CrossRefPubMedGoogle Scholar
  82. 82.
    Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997 Apr 26;349(9060):1191–7.CrossRefPubMedGoogle Scholar
  83. 83.
    Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis. 2008 Mar 1;46(5):726–31.CrossRefPubMedGoogle Scholar
  84. 84.
    Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs. 2009;11(5):349–57.CrossRefPubMedGoogle Scholar
  85. 85.
    Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006 Mar 4;367(9512):740–8.CrossRefPubMedGoogle Scholar
  86. 86.
    Shann F. Heterologous immunity and the nonspecific effects of vaccines: a major medical advance? Pediatr Infect Dis J. 2004 Jun;23(6):555–8.CrossRefPubMedGoogle Scholar
  87. 87.
    Veirum JE, Sodemann M, Biai S, Jakobsen M, Garly M, Hedegaard K, et al. Routine vaccinations associated with divergent effects on female and male mortality at the paediatric ward in Bissau, Guinea-Bissau. Vaccine. 2005 Jan 19;23(9):1197–204.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Intensive Care UnitRoyal Children’s Hospital MelbourneParkvilleAustralia

Personalised recommendations